Published in Brain on July 19, 2006
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain (2009) 7.20
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89
Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol (2010) 5.53
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov (2010) 4.55
Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci (2009) 4.50
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol (2008) 4.15
Epidemiology of Alzheimer disease. Nat Rev Neurol (2011) 4.13
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol (2010) 3.64
Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology (2009) 3.49
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron (2013) 3.27
Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci (2009) 2.76
Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol (2009) 2.66
Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol (2011) 2.57
Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. Brain (2009) 2.51
Brain β-amyloid load approaches a plateau. Neurology (2013) 2.50
Subregional neuroanatomical change as a biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 2.37
Traumatic brain injury and amyloid-β pathology: a link to Alzheimer's disease? Nat Rev Neurosci (2010) 2.34
Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology (2010) 2.20
Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci (2009) 2.16
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry (2008) 1.93
Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med (2009) 1.90
Brain fuel metabolism, aging, and Alzheimer's disease. Nutrition (2010) 1.89
Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci (2009) 1.89
Relationships between β-amyloid and functional connectivity in different components of the default mode network in aging. Cereb Cortex (2011) 1.87
Biomarkers for early detection of Alzheimer pathology. Neurosignals (2007) 1.86
Increased metabolic vulnerability in early-onset Alzheimer's disease is not related to amyloid burden. Brain (2010) 1.86
Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol Psychiatry (2009) 1.85
Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement (2013) 1.77
Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease. Neuroimage (2008) 1.74
3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging (2010) 1.70
Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol (2009) 1.67
Regional brain hypometabolism is unrelated to regional amyloid plaque burden. Brain (2015) 1.58
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Trends Neurosci (2011) 1.51
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging (2011) 1.51
Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol (2008) 1.49
Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol (2011) 1.40
Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.37
Biomarkers of Alzheimer's disease. Neurobiol Dis (2008) 1.37
Longitudinal patterns of β-amyloid deposition in nondemented older adults. Arch Neurol (2011) 1.32
Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. Am J Pathol (2011) 1.32
Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain (2015) 1.31
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid. Alzheimers Dement (2011) 1.30
Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One (2009) 1.30
Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease. Biol Psychiatry (2010) 1.29
In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging (2007) 1.29
Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis (2010) 1.28
Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med (2009) 1.27
Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol (2010) 1.24
Longitudinal cerebral blood flow and amyloid deposition: an emerging pattern? J Nucl Med (2008) 1.22
A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.21
Tau imaging in neurodegenerative diseases. Eur J Nucl Med Mol Imaging (2015) 1.21
Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol (2011) 1.20
Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? J Alzheimers Dis (2008) 1.20
Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging (2010) 1.19
Smart optical probes for near-infrared fluorescence imaging of Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging (2008) 1.17
Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J Cell Mol Med (2008) 1.16
Age and amyloid-related alterations in default network habituation to stimulus repetition. Neurobiol Aging (2011) 1.16
Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun (2014) 1.16
Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 1.15
Biomarkers in translational research of Alzheimer's disease. Neuropharmacology (2010) 1.11
ODVBA: optimally-discriminative voxel-based analysis. IEEE Trans Med Imaging (2011) 1.11
The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol (2008) 1.11
Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging (2012) 1.10
Development and evaluation of compounds for imaging of beta-amyloid plaque by means of positron emission tomography. Eur J Nucl Med Mol Imaging (2008) 1.08
Arterial spin labeling MRI: an emerging biomarker for Alzheimer's disease and other neurodegenerative conditions. Curr Opin Neurol (2012) 1.08
A review of imaging agent development. AAPS J (2009) 1.08
Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain (2006) 1.07
Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther (2011) 1.07
Update on amyloid imaging: from healthy aging to Alzheimer's disease. Curr Neurol Neurosci Rep (2009) 1.07
Optimized data preprocessing for multivariate analysis applied to 99mTc-ECD SPECT data sets of Alzheimer's patients and asymptomatic controls. J Cereb Blood Flow Metab (2010) 1.03
Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. Neuroimage Clin (2013) 1.02
Instrumental activities of daily living impairment is associated with increased amyloid burden. Dement Geriatr Cogn Disord (2011) 1.01
In vivo characterization of the early states of the amyloid-beta network. Brain (2013) 0.99
Amyloid imaging in dementias with atypical presentation. Alzheimers Dement (2012) 0.99
In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings. J Neurol (2011) 0.98
Unidirectional Influx and Net Accumulation of PIB. Open Neuroimag J (2008) 0.98
Measuring target effect of proposed disease-modifying therapies in Alzheimer's disease. Neurotherapeutics (2008) 0.97
Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. CNS Neurol Disord Drug Targets (2009) 0.97
Amyloid plaque imaging in vivo: current achievement and future prospects. Eur J Nucl Med Mol Imaging (2008) 0.96
Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiol Aging (2012) 0.96
Neuroimaging in Alzheimer's disease: current role in clinical practice and potential future applications. Clinics (Sao Paulo) (2011) 0.96
In vivo changes in microglial activation and amyloid deposits in brain regions with hypometabolism in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2010) 0.95
Disrupted Intrinsic Networks Link Amyloid-β Pathology and Impaired Cognition in Prodromal Alzheimer's Disease. Cereb Cortex (2014) 0.94
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol (2012) 0.94
Alzheimer's disease and epilepsy: insight from animal models. Future Neurol (2012) 0.94
Staging Alzheimer's disease progression with multimodality neuroimaging. Prog Neurobiol (2011) 0.92
Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology (2014) 0.92
Multimodal Imaging of Alzheimer Pathophysiology in the Brain's Default Mode Network. Int J Alzheimers Dis (2011) 0.91
Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One (2012) 0.90
Role of HIV in amyloid metabolism. J Neuroimmune Pharmacol (2014) 0.90
In vivo human amyloid imaging. Curr Alzheimer Res (2011) 0.90
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging (2007) 4.47
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab (2006) 2.02
Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology (2012) 2.02
Acute kidney injury following severe trauma: Risk factors and long-term outcome. J Trauma Acute Care Surg (2015) 2.02
Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry (2002) 1.87
Rapid bone and blood flow formation in impacted morselized allografts: positron emission tomography (PET) studies on allografts in 5 femoral component revisions of total hip arthroplasty. Acta Orthop Scand (2003) 1.82
Genetic and environmental contributions to abdominal aortic aneurysm development in a twin population. J Vasc Surg (2009) 1.80
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol (2003) 1.65
Chronic whiplash symptoms are related to altered regional cerebral blood flow in the resting state. Eur J Pain (2008) 1.55
Neurogenic neuroepithelial and radial glial cells generated from six human embryonic stem cell lines in serum-free suspension and adherent cultures. Glia (2007) 1.51
Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology (2013) 1.51
Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos (2008) 1.50
Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol (2008) 1.50
A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci (2008) 1.47
Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. Neurosci Lett (2004) 1.47
GMP--three letters with many interpretations. Protection of patients or killing the clinical and research applications of PET? Eur J Nucl Med Mol Imaging (2008) 1.39
Ventilation distribution studies comparing Technegas and "Gallgas" using 68GaCl3 as the label. J Nucl Med (2011) 1.39
Up-regulation of the inflammatory cytokines IFN-gamma and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APP(SWE) transgenic mice. J Neuroimmunol (2002) 1.36
Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease. Acta Neurol Scand Suppl (2003) 1.30
In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging (2007) 1.29
A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl (2003) 1.29
Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry (2004) 1.28
Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol (2010) 1.26
18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med (2011) 1.26
Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. Neurobiol Aging (2010) 1.24
Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry (2005) 1.23
Clinical validation of 18F-AZD4694, an amyloid-β-specific PET radioligand. J Nucl Med (2012) 1.22
A European multicentre PET study of fibrillar amyloid in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 1.21
Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging (2007) 1.21
Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med (2012) 1.19
Amygdala and anterior cingulate cortex activation during affective startle modulation: a PET study of fear. Eur J Neurosci (2003) 1.18
PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci (2004) 1.17
Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage (2006) 1.17
Preparation and evaluation of (68)Ga-DOTA-hEGF for visualization of EGFR expression in malignant tumors. J Nucl Med (2005) 1.16
PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl) (2006) 1.15
Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment. Neuroimage (2003) 1.14
In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. Nucl Med Biol (2010) 1.12
[11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab (2006) 1.11
Evidence-based evaluation of magnetic resonance imaging as a diagnostic tool in dementia workup. Top Magn Reson Imaging (2005) 1.11
[(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int (2008) 1.11
The role of PET in localization of neuroendocrine and adrenocortical tumors. Ann N Y Acad Sci (2002) 1.09
In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med (2012) 1.09
Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging (2011) 1.09
Dual effects of nicotine on oxidative stress and neuroprotection in PC12 cells. Neurochem Int (2003) 1.09
Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue. Brain (2013) 1.09
Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. Proc Natl Acad Sci U S A (2007) 1.08
Imaging the pathology of Alzheimer's disease: amyloid-imaging with positron emission tomography. Neuroimaging Clin N Am (2003) 1.07
Smoking during pregnancy: a way to transfer the addiction to the next generation? Respiration (2002) 1.07
Brain regions involved in fatigue sensation: reduced acetylcarnitine uptake into the brain. Neuroimage (2002) 1.05
Restricted cortical and amygdaloid removal of vesicular glutamate transporter 2 in preadolescent mice impacts dopaminergic activity and neuronal circuitry of higher brain function. J Neurosci (2009) 1.04
In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry (2003) 1.03
Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo. Neurobiol Aging (2010) 1.01
Small-molecule biomarkers for clinical PET imaging of apoptosis. J Nucl Med (2010) 0.99
Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol (2003) 0.99
A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci (2005) 0.99
Noise correlation in PET, CT, SPECT and PET/CT data evaluated using autocorrelation function: a phantom study on data, reconstructed using FBP and OSEM. BMC Med Imaging (2005) 0.98
Unidirectional Influx and Net Accumulation of PIB. Open Neuroimag J (2008) 0.98